GlaxoSmithKline has signed an agreement with MolMed S.p.A. under which MolMed will develop a production process for an investigational gene therapy for ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency), a very rare and life-threatening disease that affects approximately 350 children worldwide. Milan-based MolMed will receive as much as $7.8 million in revenues over a two-year period. ADA-SCID is a disease caused by the alteration of a single gene. A therapy has...